Moreover, various monoclonal antibodies targeting IL-6 signalling, such as Situximab and Tocilizumab, have demonstrated antitumour efficacy against cancer, further solidifying the importance of IL-6 in tumour growth [38]. This evidence concerns the gene IL6 and neoplasm.